Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Tamoxifen vs Aromatase Inhibitors and highlights of San Antonio Breast Cancer Symposium

Bookmark and Share

SABCS 2008

10 - 14 Dec 2008
Published: 9 Jan 2009
Views: 17626
Rating:
Save
Professor Mitch Dowsett, Professor of Biochemical Endocrinology at the Institute of Cancer Research
Highlights of the San Antonio Breast Cancer Symposium, Aromatase Inhibtors vs Tamoxifen, Survival Benefit, BIG 1-98, Letrozole

Related Videos

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
Spindle cell lesions of the breast
Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland
Spindle cell lesions of the breast ( Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland )
1 Feb 2023
Management of HER2 positive metastatic breast cancer treatment algorithm
Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA
Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )
31 Jan 2023
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
13 Jan 2023
A genomic assay may predict long-term prognosis in premenopausal patients with...
Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022
Lasofoxifene shows promise for women with ESR1-mutated mBC
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...
Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )
4 Jun 2022
The RxPONDER trial and its impact on best clinical practice
Prof Christos Markopoulos and Prof Giuseppe Curigliano
The RxPONDER trial and its impact on best clinical practice ( Prof Christos Markopoulos and Prof Giuseppe Curigliano )
17 Dec 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation